KEDI Global Obesity Care Industry Top 2+ Index

Amgen Q1 2026 earnings conference call is scheduled for April 30, 2026; a high price impact (>=10%) is expected based on historical volatility, scheduled.

The FDA's Oncologic Drugs Advisory Committee (ODAC) is scheduled to review two of AstraZeneca's oncology applications on April 30, 2026; medium importance estimated due to 5% price impact, scheduled

Merck is scheduled to release its first-quarter 2026 financial results on April 30, 2026; earnings releases typically result in moderate price volatility, scheduled.

Eli Lilly is scheduled to report Q1 2026 earnings on April 30, 2026 scheduled.

AstraZeneca is scheduled to release its Q1 2026 earnings results on April 29, 2026, before the market opens; high importance estimated due to potential for 10% price impact, scheduled

First quarter 2026 earnings results are scheduled to be released on April 28, 2026, which is scheduled.

First quarter 2026 earnings release is scheduled for April 16, 2026; high impact is estimated as earnings results typically drive significant price movement, scheduled.

The FDA is expected to approve the first generic versions of AstraZeneca's Farxiga (dapagliflozin) tablets on April 8, 2026; medium importance estimated due to 5% price impact from competition, scheduled

Announced the debut of its first luxury athletic country club in Idaho, a 135,000-square-foot facility in the Boise area, on April 8, 2026, as part of its 2026 expansion plans.

Founder Chip Wilson initiated a proxy fight by filing a DFAN14A on April 7, 2026, seeking to elect three new independent directors to the board. The campaign cites concerns over governance, brand erosion, and a lack of creative leadership on the current board.

Amgen announced positive Phase 3 results for subcutaneous TEPEZZA on April 6, 2026; a high price impact (>=10%) is expected due to significant market expansion potential, expected.